MAPT and Alzheimer disease: The platform basket trials, which evaluate a single targeted therapy on multiple diseases; or umbrella trials, which test multiple interventions in a single disease (96) can be feasible option to test a single drug in multiple neurodegenerative processes, for instance AD and PD, or to test one drug in multiple disease, for instance, an anti-tau therapy and AD and other tauopathies.